Know How COVID-19 Oral Antivirals Compare

You'll start to see the new COVID-19 oral antivirals, nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.

Either is an option for outpatients with COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.

They're started within 5 days of symptoms...and patients don't currently have to pay for these meds.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote